Systemic Inflammation in Pregnant Women With Latent Tuberculosis Infection.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2020
Historique:
received: 26 07 2020
accepted: 09 12 2020
entrez: 15 2 2021
pubmed: 16 2 2021
medline: 17 7 2021
Statut: epublish

Résumé

Recent studies in adults have characterized differences in systemic inflammation between adults with and without latent tuberculosis infection (LTBI+ We conducted a cohort study of 155 LTBI+ and 65 LTBI- pregnant women, stratified by HIV status, attending an antenatal clinic in Pune, India. LTBI status was assessed by interferon gamma release assay. Plasma was used to measure systemic inflammation markers using immunoassays: IFN Study population was a median age of 23 (Interquartile range: 21-27), 28% undernourished (mid-upper arm circumference (MUAC) <23 cm), 12% were vegetarian, 10% with gestational diabetes and 32% with HIV. In multivariable models, LTBI+ women had significantly lower levels of third trimester AGP, IL1β, sCD163, IL-6 and IL-17a. Interestingly, in exploratory analysis, LTBI+ TB progressors had significantly higher levels of IL1 Our data shows a distinct systemic immune profile in LTBI+ pregnant women compared to LTBI- women. Data from our exploratory analysis suggest that LTBI+ TB progressors do not have this immune profile, suggesting negative association of this profile with TB progression. If other studies confirm these differences by LTBI status and show a causal relationship with TB progression, this immune profile could identify subsets of LTBI+ pregnant women at high risk for TB progression and who can be targeted for preventative therapy.

Sections du résumé

Background
Recent studies in adults have characterized differences in systemic inflammation between adults with and without latent tuberculosis infection (LTBI+
Methods
We conducted a cohort study of 155 LTBI+ and 65 LTBI- pregnant women, stratified by HIV status, attending an antenatal clinic in Pune, India. LTBI status was assessed by interferon gamma release assay. Plasma was used to measure systemic inflammation markers using immunoassays: IFN
Results
Study population was a median age of 23 (Interquartile range: 21-27), 28% undernourished (mid-upper arm circumference (MUAC) <23 cm), 12% were vegetarian, 10% with gestational diabetes and 32% with HIV. In multivariable models, LTBI+ women had significantly lower levels of third trimester AGP, IL1β, sCD163, IL-6 and IL-17a. Interestingly, in exploratory analysis, LTBI+ TB progressors had significantly higher levels of IL1
Conclusions
Our data shows a distinct systemic immune profile in LTBI+ pregnant women compared to LTBI- women. Data from our exploratory analysis suggest that LTBI+ TB progressors do not have this immune profile, suggesting negative association of this profile with TB progression. If other studies confirm these differences by LTBI status and show a causal relationship with TB progression, this immune profile could identify subsets of LTBI+ pregnant women at high risk for TB progression and who can be targeted for preventative therapy.

Identifiants

pubmed: 33584652
doi: 10.3389/fimmu.2020.587617
pmc: PMC7873478
doi:

Substances chimiques

Antigens, CD 0
Antigens, Differentiation, Myelomonocytic 0
CD163 antigen 0
Cytokines 0
Orosomucoid 0
Receptors, Cell Surface 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

587617

Subventions

Organisme : NICHD NIH HHS
ID : R00 HD089753
Pays : United States
Organisme : NICHD NIH HHS
ID : R01 HD081929
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI069465
Pays : United States
Organisme : NIAID NIH HHS
ID : K23 AI129854
Pays : United States

Informations de copyright

Copyright © 2021 Naik, Alexander, Kumar, Kulkarni, Deshpande, Yadana, Leu, Araújo-Pereira, Andrade, Bhosale, Babu, Gupta, Mathad and Shivakoti.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer GW declared a past co-authorship with one of the authors BA to the handling editor.

Références

Clin Infect Dis. 2012 Dec;55(11):1532-49
pubmed: 22942202
J Immunol. 2013 Jun 15;190(12):6533-41
pubmed: 23667107
Clin Infect Dis. 2012 Mar;54(6):784-91
pubmed: 22267721
Lancet Infect Dis. 2004 Dec;4(12):761-76
pubmed: 15567126
Am J Reprod Immunol. 2010 Jun;63(6):425-33
pubmed: 20367629
Pathog Immun. 2016 Fall-Winter;1(2):291-303
pubmed: 27853753
J Immunol. 2014 Jan 15;192(2):676-82
pubmed: 24337386
Am J Respir Crit Care Med. 2012 Apr 1;185(7):779-84
pubmed: 22161161
Eur Respir J. 2020 Mar 20;55(3):
pubmed: 31862768
Am J Epidemiol. 2000 Aug 1;152(3):247-63
pubmed: 10933272
Clin Infect Dis. 2018 Mar 5;66(6):886-892
pubmed: 29069328
PLoS One. 2013 May 21;8(5):e64008
pubmed: 23700446
Cell Mol Immunol. 2018 Mar;15(3):216-225
pubmed: 29176747
Am J Reprod Immunol. 2002 Feb;47(2):72-81
pubmed: 11900591
J Acquir Immune Defic Syndr. 2020 Aug 1;84(4):430-436
pubmed: 32282443
Clin Infect Dis. 2019 Nov 25;:
pubmed: 31761933
Am J Obstet Gynecol. 1998 Jul;179(1):80-6
pubmed: 9704769
Am J Epidemiol. 1974 Feb;99(2):131-8
pubmed: 4810628
Int J Biochem Cell Biol. 2012 Jun;44(6):942-54
pubmed: 22426116
Annu Rev Immunol. 2013;31:475-527
pubmed: 23516984
Eur Respir J. 2011 May;37(5):1248-59
pubmed: 20817712
Immunity. 2009 Nov 20;31(5):761-71
pubmed: 19913447
PLoS Pathog. 2014 Oct 16;10(10):e1004426
pubmed: 25329476
Front Pediatr. 2019 Aug 27;7:350
pubmed: 31508399
J Infect Dis. 2013 Apr 15;207(8):1253-61
pubmed: 23359591
J Exp Med. 2011 Oct 24;208(11):2251-62
pubmed: 21967766
Eur Respir J. 2009 May;33(5):956-73
pubmed: 19407047
Immunol Rev. 2015 Mar;264(1):88-102
pubmed: 25703554
Clin Exp Immunol. 2012 Feb;167(2):317-29
pubmed: 22236009
Nat Rev Microbiol. 2009 Dec;7(12):845-55
pubmed: 19855401
PLoS One. 2018 Sep 13;13(9):e0202191
pubmed: 30212453
PLoS Curr. 2013 Jun 07;5:
pubmed: 23787989
Lancet Infect Dis. 2003 Sep;3(9):578-90
pubmed: 12954564
Tuberculosis (Edinb). 2008 May;88(3):203-11
pubmed: 18055265

Auteurs

Shilpa Naik (S)

Byramjee-Jeejeebhoy Government Medical College-Johns Hopkins University Clinical Research Site, Pune, India.
Department of Obstetrics and Gynecology, Byramjee Jeejeebhoy Government Medical College, Pune, India.

Mallika Alexander (M)

Byramjee-Jeejeebhoy Government Medical College-Johns Hopkins University Clinical Research Site, Pune, India.

Pavan Kumar (P)

International Center for Excellence in Research, National Institutes of Health, National Institute for Research in Tuberculosis, Chennai, India.

Vandana Kulkarni (V)

Byramjee-Jeejeebhoy Government Medical College-Johns Hopkins University Clinical Research Site, Pune, India.

Prasad Deshpande (P)

Byramjee-Jeejeebhoy Government Medical College-Johns Hopkins University Clinical Research Site, Pune, India.

Su Yadana (S)

Department of Epidemiology, Columbia University Mailman School of Public Health, New York, NY, United States.

Cheng-Shiun Leu (CS)

Department of Biostatistics, Columbia University Mailman School of Public Health, New York, NY, United States.

Mariana Araújo-Pereira (M)

Instituto Goncalo Moniz, Fundação Oswaldo Cruz, Salvador, Brazil.
Multinational Organization Network Sponsoring Translational and Epidemiological Research, Fundação José Silveira, New York, NY, Brazil.
Faculdade de Medicina, Universidade Federal da Bahia, Salvador, Brazil.

Bruno B Andrade (BB)

Instituto Goncalo Moniz, Fundação Oswaldo Cruz, Salvador, Brazil.
Multinational Organization Network Sponsoring Translational and Epidemiological Research, Fundação José Silveira, New York, NY, Brazil.
Faculdade de Medicina, Universidade Federal da Bahia, Salvador, Brazil.
Curso de Medicina, Faculdade de Tecnologia e Ciências, Salvador, Brazil.
Escola de Medicina, Universidade Salvador (UNIFACS), Laureate International Universities, Salvador, Brazil.
Curso de Medicina, Escola Bahiana de Medicina e Saúde Pública (EBMSP), Salvador, Brazil.

Ramesh Bhosale (R)

Byramjee-Jeejeebhoy Government Medical College-Johns Hopkins University Clinical Research Site, Pune, India.
Department of Obstetrics and Gynecology, Byramjee Jeejeebhoy Government Medical College, Pune, India.

Subash Babu (S)

International Center for Excellence in Research, National Institutes of Health, National Institute for Research in Tuberculosis, Chennai, India.

Amita Gupta (A)

Byramjee-Jeejeebhoy Government Medical College-Johns Hopkins University Clinical Research Site, Pune, India.
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States.

Jyoti S Mathad (JS)

Department of Medicine, Weill Cornell Medical College, New York, NY, United States.

Rupak Shivakoti (R)

Department of Epidemiology, Columbia University Mailman School of Public Health, New York, NY, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH